SPAC Semper Paratus Acquisition Corp. (NASDAQ:LGST) shareholders have approved a planned merger with immunotherapy developer Tevogen Bio (TVGN).
Semper said in a statement issued Thursday that it was still working on satisfying closing conditions for the deal. It didn’t say when it though the deal would close.
After the closing, shares of the combined company are expected to trade on Nasdaq under the symbol TVGN.
Semper and Tevogen announced plans to merge in June, with the deal estimating the equity and enterprise value of the combined company at around $1.2B.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.